☆ 4.7 Article

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

JOURNAL OF CLINICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa et al.

Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Hematology

Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice

Sagar Lonial et al.

Lancet Haematology (2022)

Add to Collection

Article Hematology

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

Cirino Botta et al.

Summary: Large-scale immune monitoring is increasingly used in clinical trials, but manual interpretation of multidimensional data poses challenges. FlowCT is a semi-automated workspace that can analyze large datasets, including preprocessing, normalization, dimensionality reduction, clustering, and predictive modeling tools.

BLOOD ADVANCES (2022)

Add to Collection

Review Hematology

How I approach smoldering multiple myeloma

Iuliana Vaxman et al.

Summary: This review discusses the current standard of care for smoldering multiple myeloma and efforts to understand its progression to active multiple myeloma. Two patient cases are presented to illustrate that sometimes patients can undergo observation only, even when they exceed criteria for high-risk smoldering multiple myeloma.

BLOOD (2022)

Add to Collection

Article Hematology

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo et al.

Summary: Since 1994, the classification of lymphoid neoplasms has been continuously updated through international efforts, with recent progress driven by genomic studies. This proposal presents the International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors, which has refined diagnostic criteria and incorporated new insights from genomics.

BLOOD (2022)

Add to Collection

Letter Hematology

Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials

Mohammad Ahsen Soomro et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile

Davine Hofste Op Bruinink et al.

Summary: This study successfully identified pPCL and classified 10% of NDMM tumors as PCL-like by constructing a transcriptomic classifier, indicating the presence of a specific transcriptome in high-risk NDMM patients. The PCL-like status showed significant prognostic value in outcome assessment, potentially improving the accuracy of current risk models.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Mattia D'Agostino et al.

Summary: In this study, the Revised International Staging system (R-ISS) for intermediate-risk multiple myeloma patients was revised based on the additive value of each single risk feature.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Luca Bertamini et al.

Summary: This study aimed to investigate the relationship between levels of circulating tumor plasma cells (CTC) and prognosis in patients with multiple myeloma, as well as to determine the optimal cutoff value. The results showed that CTC levels above the optimal cutoff were associated with shorter progression-free survival and overall survival. The only factor that reduced the negative impact of high CTC levels was achieving minimal residual disease negativity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

Juan-Jose Garces et al.

Summary: In patients with newly diagnosed MM, CTCs were detected in 92% of cases and showed a modest correlation with BM PCs. Increasing percentages of CTCs were associated with inferior PFS, with a cutoff of 0.01% CTCs showing independent prognostic value.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

Modern Myeloma Therapy plus Sustained Minimal Residual Disease-Negative = (Functional) Cure!

Ola Landgren et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Rita Alaggio et al.

Summary: This article provides an overview of the upcoming 5th edition of the World Health Organization classification of lymphoid tumors, highlighting changes from the previous edition such as reorganization of entities, modification of nomenclature, revision of diagnostic criteria, deletion of entities, introduction of new entities, and inclusion of tumor-like lesions.

LEUKEMIA (2022)

Add to Collection

Article Medicine, General & Internal

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Paul G. Richardson et al.

Summary: In patients with newly diagnosed multiple myeloma, adding autologous stem-cell transplantation to triplet therapy (RVD) can prolong progression-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Faith E. Davies et al.

Summary: The treatment landscape of multiple myeloma has undergone significant changes, leading to improved survival rates. However, clinical outcomes still vary, with some patients not benefiting from current approaches. By evaluating clinical and biochemical parameters, as well as tumor-acquired genetic variants, it is possible to predict variability in treatment outcomes and implement risk stratification and personalized therapies.

BLOOD CANCER DISCOVERY (2022)

Add to Collection

Article Hematology

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Jesse M. Tettero et al.

Summary: Experts from the MRD Working Party of the European LeukemiaNet evaluated the key factors for accurate MFC-MRD measurement in acute myeloid leukemia (AML) and provided recommendations to ensure quality and reproducibility of results. The recommendations were tested by comparing two 8-color MRD panels in multiple laboratories, confirming their feasibility.

HEMASPHERE (2022)

Add to Collection

Article Hematology

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Ibai Goicoechea et al.

Summary: An analysis of patients with multiple myeloma revealed that undetectable measurable residual disease (MRD) predicts higher progression-free survival, and identified differences in MRD resistance mechanisms between patients with standard and high-risk cytogenetic abnormalities.

BLOOD (2021)

Add to Collection

Article Hematology

Persistent challenges with treating multiple myeloma early

Aaron M. Goodman et al.

Summary: Over the past decade, there have been advancements in the treatment of multiple myeloma and its precursor diseases, including expanding the definition to include patients without end organ damage and treating high-risk, smoldering cases. Despite the potential benefits, such as improved survival and quality of life, the implications of early treatment in this context remain uncertain.

BLOOD (2021)

Add to Collection

Meeting Abstract Hematology

Curative Strategy (GEM- CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Maria-Victoria Mateos et al.

BLOOD (2021)

Add to Collection

Article Hematology

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser et al.

Summary: The European LeukemiaNet MRD Working Party updated the 2018 MRD recommendations, including technical specifications and integrative assessments. They also proposed the use of MRD as a prognostic and surrogate endpoint for drug testing, as well as the clinical implications of MRD assessment in AML. Recommendations include technical requirements for flow cytometry and molecular MRD analysis, as well as reporting methods for MRD results.

BLOOD (2021)

Add to Collection

Article Multidisciplinary Sciences

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

Eileen M. Boyle et al.

Summary: The study found that smoldering myeloma (SMM) has fewer NRAS and FAM46C mutations, as well as fewer adverse translocations, when compared to newly diagnosed myeloma. KRAS mutations are associated with a shorter time to progression. Changes in clonal structure, branching evolutionary patterns, and other genetic mechanisms may underlie the transition from SMM to MM, providing insights for early intervention strategies.

NATURE COMMUNICATIONS (2021)

Add to Collection

Letter Oncology

Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models

Elizabeth Hill et al.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M. A. Dimopoulos et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Hematology

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde

Pellegrino Musto et al.

Summary: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by specific criteria, with a median time to progression of approximately 5 years. The prognosis and management of SMM patients present challenges due to the potential for rapid transformation into symptomatic disease. While traditional approach involves close observation until progression, recent clinical trials have shown significant benefits for high-risk SMM patients treated with specific medications.

HAEMATOLOGICA (2021)

Add to Collection

Article Medicine, General & Internal

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

E. Kastritis et al.

Summary: In patients with newly diagnosed AL amyloidosis, adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in higher rates of hematologic complete response and improved survival outcomes. However, adverse events, including lymphopenia, pneumonia, cardiac failure, and diarrhea, were more common in the daratumumab group. Most deaths were due to amyloidosis-related cardiomyopathy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

Bruno Paiva et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma

Sagar Lonial et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Letter Oncology

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma

Maximilian Merz et al.

LEUKEMIA (2020)

Add to Collection

Article Oncology

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

Mark Bustoros et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Maria-Victoria Mateos et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Oncology

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

Paula Rodriguez-Otero et al.

BLOOD CANCER JOURNAL (2019)

Add to Collection

Article Hematology

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Laura Rosinol et al.

BLOOD (2019)

Add to Collection

Article Oncology

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

Noemi Puig et al.

LEUKEMIA (2019)

Add to Collection

Article Medical Laboratory Technology

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Andy C. Rawstron et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)

Add to Collection

Article Multidisciplinary Sciences

Genomic patterns of progression in smoldering multiple myeloma

Niccolo Bolli et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Oncology

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Juan-Jose Lahuerta et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

Eli Muchtar et al.

BLOOD (2017)

Add to Collection

Article Hematology

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Maria-Victoria Mateos et al.

BLOOD (2016)

Add to Collection

Article Hematology

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Bruno Paiva et al.

BLOOD (2016)

Add to Collection

Article Oncology

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

B. Paiva et al.

LEUKEMIA (2013)

Add to Collection

Article Medicine, General & Internal

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

Maria-Victoria Mateos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Hematology

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Bruno Paiva et al.

BLOOD (2012)

Add to Collection

Article Hematology

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Laura Rosinol et al.

BLOOD (2012)

Add to Collection

Article Oncology

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

J. J. M. van Dongen et al.

LEUKEMIA (2012)

Add to Collection

Article Hematology

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

Bruno Paiva et al.

BLOOD (2011)

Add to Collection

Article Medical Laboratory Technology

A GEIL Flow Cytometry Consensus Proposal for Quantification of Plasma Cells: Application to Differential Diagnosis Between MGUS and Myeloma

Elise Frebet et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2011)

Add to Collection

Article Oncology

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

Maria-Victoria Mateos et al.

LANCET ONCOLOGY (2010)

Add to Collection

Article Hematology

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Bruno Paiva et al.

BLOOD (2008)

Add to Collection

Article Hematology

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Andy C. Rawstron et al.

HAEMATOLOGICA (2008)

Add to Collection

Article Oncology

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

Juan Jose Lahuerta et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma

Robert A. Kyle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Add to Collection

Article Hematology

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

Fenghuang Zhan et al.

BLOOD (2007)

Add to Collection

Article Oncology

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis

A Dispenzieri et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.